Background: Facial comedolytic studies allow testing of a maximum of two products. The upper back provides a larger area with a more uniform distribution of microcomedones for comedolytic studies.
Objective: To design a multi-sample method for assessing comedolytic activity of topical products on the back. The effect of season on product discrimination was also explored.
Methods: Three cleansing formulations (products B, C and D), a negative water control and 0.025% Retin-A cream (positive control) were tested. Seven subjects were recruited in summer and nine in fall. Products were applied for 8 weeks, comedolysis was assessed by visually evaluating cyanoacrylate follicular biopsies taken at baseline and post-treatment.
Results: In all data sets (summer, fall and combined), sites treated with Retin-A had a significantly lower number of microcomedones as compared to the negative water control. In addition, cleansers B and D showed a significant reduction from baseline in the fall and combined (summer and fall) data, but not in summer data alone indicating different responses to treatment during the year.
Conclusions: The design was sensitive enough to detect differences between cleansing formulations under normal washing conditions. Reduced sensitivity observed during summer suggests hot humid conditions may decrease the comedolytic performance of topical products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1467-2494.2004.00229.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring melatonin's signalling pathways in the protection against age-related skin deterioration.
Pharmacol Rep
January 2025
Razi Drug Research Centre, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Melatonin, renowned for regulating sleep-wake cycles, also exhibits notable anti-aging properties for the skin. Synthesized in the pineal gland and various tissues including the skin, melatonin's efficacy arises from its capacity to combat oxidative stress and shield the skin from ultraviolet (UV)-induced damage. Moreover, it curbs melanin production, thereby potentially ameliorating hyperpigmentation.
View Article and Find Full Text PDFEmerging strategies for nitric oxide production and their topical application as nanodressings to promote diabetic wound healing.
J Nanobiotechnology
January 2025
Department of Biobmedical Engineering and Technology, Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
The challenges associated with prolonged healing or non-healing of chronic diabetic wounds contribute significantly to the increased incidence of lower limb amputation. A pivotal factor in the impediment of healing is the reduced production of endogenous nitric oxide (NO) due to the hyperglycemic microenvironment typical of chronic diabetes. While both endogenous and exogenous NO have been shown to promote the healing process of diabetic wounds, the direct application of NO in wound management is limited due to its gaseous nature and the risk of explosive release.
View Article and Find Full Text PDFAugmented silver sulfadiazine nanostructured lipid carriers impregnated collagen sponge for promoting burn wound healing.
Int J Biol Macromol
January 2025
Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, P.O. Box 32897, Menoufia, Egypt; Nanomedicine Laboratory, Faculty of Pharmacy, University of Sadat City, P.O. Box 32897, Sadat City, Egypt. Electronic address:
Silver sulfadiazine (SSD) is a widely used antibacterial agent for burn wound treatment owing to its capability in re-epithelialization and wound healing. However, due to its low solubility, the need for an effective drug delivery system is mandatory. This study aimed to optimize SSD nanostructured lipid-based carriers (NLCs), incorporated in a collagen sponge form as an innovative topical dosage form for effective burn wound treatment.
View Article and Find Full Text PDFBaricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Oral and topical spironolactone in acne treatment: A meta-analysis of effectiveness and safety.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Faculty of Medicine, Cairo University, Cairo, Egypt.
Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!